have illustrated the therapeutic potential of human iPSC-ECs in preclinical animal models of retinopathy, myocardial infarction, and hindlimb ischemia. [10] [11] [12] iPSC-ECs also serve as an effective platform for vascular disease modeling and drug screening. Patient-specific iPSC-ECs have been used to successfully recapitulate in vitro the clinical phenotype of pulmonary arterial hypertension, fibrodysplasia ossificans progressiva, diabetes mellitus, calcified aortic valvular disease, and cardiomyopathies. [13] [14] [15] In addition, iPSC-ECs have been used to generate organoids or bioengineered 3-dimensional organ structures. 16, 17 However, there currently exist several limitations with the iPSC-EC technology that must be addressed. 6 First, the iPSC-EC differentiation protocol is not fully optimized and remains inefficient. The percentage of bona fide ECs obtained from the current differentiation protocols is low and variable. Heterogeneity of the iPSC-ECs has not been resolved, as the subpopulations of iPSC-ECs remain undetermined. 18 Reported methods to date for generating specific subtypes of iPSC-ECs are limited. 19 To resolve these issues, we performed large-scale singlecell RNA sequencing (scRNA-seq) across the iPSC-EC differentiation to identify heterogeneous populations of iPSC-ECs. Droplet-based scRNA-seq is a powerful, state-of-the-art tool in analyzing transcriptome of thousands of cells in parallel. 20, 21 In contrast to the plate-based or automated microfluidic-based scRNA-seq techniques that are limited to analysis of tens to hundreds of cells, microdroplet-based scRNA-seq allows parallel analysis of thousands of cells per experiment, enabling comprehensive characterization of heterogeneous cell populations. 22 In this study, we identified bona fide iPSC-EC cluster during the differentiation process, which exclusively expressed endothelial-specific genes. We characterized various non-EC types of mesodermal lineage generated during differentiation. Last, we identified 4 major subpopulations of iPSC-ECs marked by robust enrichment of CLDN5 (claudin-5), APLNR (apelin receptor), GJA5 (gap junction α5), and ESM1 (endothelial cell-specific molecule 1) genes, respectively. Enabled by massively parallel scRNA-seq analysis, our findings uncover the inefficiency of iPSC-EC differentiation and heterogeneity of human iPSC-ECs.
Methods
All data have been made publicly available at Gene Expression Omnibus datasets and can be accessed at GSE116555 or from the corresponding author on request.
Detailed Methods section is available in the Online Data Supplement.
Results

Differentiation of Human iPSCs to Bona Fide ECs
Human iPSCs were differentiated using a monolayer-based, serum-free protocol as previously described. 15, 23 In brief, the iPSCs were treated with 6 µmol/L CHIR from day 0 to 2 and 2 µmol/L CHIR from day 2 to 4 to generate mesoderm. From day 4 to 12 of differentiation, cells were treated with VEGF, bFGF (basic fibroblast growth factor), and BMP4 (bone morphogenetic protein 4) in EGM2 endothelial growth media to promote specification to ECs. On day 12 of differentiation, bona fide ECs were positively selected by magnetic activated cell sorting using bead-conjugated CD (cluster of differentiation) 144 antibody ( Figure 1A ). The sorted iPSC-ECs express endothelial-specific transcription regulator ERG (ETS-related gene) and endothelialspecific cadherin protein VE-cadherin (also known as CD144 or CDH5; Online Figure IA and IB). The iPSC-ECs exhibited cobblestone-like morphology, formed tube-like networks on Matrigel substrate, and migrated in wound scratch assay, demonstrating endothelial identity and function (Online Figure IC) . The iPSC-ECs also generated NO (Online Figure ID 
Large-Scale scRNA-Seq of Days 8 and 12 of iPSC-EC Differentiation
Large-scale scRNA-seq (10X Genomics) was performed on differentiating iPSCs at days 8 and 12 of EC differentiation. Seurat R package was used to log-normalize and analyze data. 24 Cells with a clear outlier number of genes were perceived as potential multiplets and excluded from subsequent analyses-cells with 3500+ genes in day 8 sample and 4000+ genes in day 12 sample were, therefore, excluded from downstream analysis (Online Figure II) . Likewise, cells with mitochondrial gene percentage of ≥0.05% were excluded in both samples (Online Figure II) . A total of 3259 cells and 2414 cells were captured in day 8 and 12 samples, respectively (Online Table I ). Statistically significant principal components were determined (Online Figure III) , and nonlinear dimensional reduction (t-SNE [t-distributed stochastic neighbor embedding]) to 2 t-SNE dimensions was performed, resulting in 10 clusters of cells for day 8 cells and 8 clusters for day 12 cells (Figure 1B and 1C) . Each cluster is defined by a unique set of differentially expressed genes. 20 Heatmaps show highly differentially expressed genes for each cluster of cells ( Figure 1D and 1E). Individual clusters possess variable number of cells, ranging from 71 to 726 cells per cluster (Figure 2A ).
Identification of iPSC-Derived ECs
To identify the cell cluster(s) representative of bona fide iPSCECs, expression of known markers of ECs was visualized by ViolinPlot and FeaturePlot functions of Seurat. 20 Early EC markers (eg, CD34, KLF2, and ECSCR) were expressed exclusively in cluster 7 of day 8 sample and in cluster 5 of day 12 sample (Figure 2B ). Mature EC markers (eg, CDH5, ERG, and FLT1) were similarly expressed in identical clusters in each of the 2 samples, respectively ( Figure 2C ). The level of expression and number of cells expressing both early and mature endothelial markers were markedly increased in the iP-SC-EC cluster on day 12 than in day 8. Expression of non-EC markers, such as ACTA2 (mesenchymal), TNNT2 (cardiac), and KIT (hematopoietic), was absent in the iPSC-EC clusters ( Figure 2D ), indicating these clusters were exclusively endothelial and transcriptionally distinct from other cell types.
Canonical Correlation Analysis of Day 8 and Day 12 iPSC-EC Differentiation
To track differentiating cells from day 8 to 12, canonical correlation analysis of scRNA-seq data of the 2 differentiation days was performed using the Seurat package. Canonical correlation analysis combined the 2 datasets and clustered cells with similar transcriptomic profiles ( Figure 3A and 3B) . Single integrated analysis of the combined datasets then defined 7 individual clusters (termed CC0 to CC6) from cells pooled from both datasets ( Figure 3C ; Online Table II) . Hierarchical analysis showed the greatest transcriptomic similarity among the 4 clusters CC0, CC5, CC2, and CC3. Cluster CC4 showed some similarity to this group of clusters, whereas clusters CC6 and CC1 were more distinctive ( Figure 3D ). To elucidate the differentiation process of cells in each cluster, the number of cells per cluster at the 2 days of differentiation was counted ( Figure 3E ). Cell numbers in clusters CC0, CC2, CC3, and CC6 decreased from day 8 to 12, whereas cell numbers in clusters CC1, CC4, and CC5 increased from day 8 to 12. The greatest increase in cell number occurred in CC1 (≈10-fold), followed by CC4 (≈2.5-fold). To identify the biological function and cell identity of each cluster, pathway enrichment analysis was performed to reveal statistically significant gene ontologies for each cluster ( Figure 3F ).
Based on this information, CC4 was identified as the bona fide iPSC-EC cluster that expressed genes known to regulate blood vessel development, vasculature development, endothelium development, and angiogenesis (Online Figure IVA and  IVB) . Furthermore, cellular interaction and molecular cross talk, such as ligand-to-receptor interactions among the clusters were determined at the transcriptomic level ( Figure 3G ; Online Figures IVC, IVD, and V). Using these approaches, cell identities for all clusters were determined ( Figure 3H ). Clusters CC0, CC2, CC3, and CC5 were TNNT2-high cardiomyogenic cells. Cluster CC0 represented SLN (sarcolipin) and TMEM88-high atrial-like cardiomyocytes, which also displayed expression of mesenchymal genes, such as LUM, ACTA2, and IGFBP3 (Online Table II ). CC5 represented TNNI1 (troponin I1)-high cardiomyocytes with immature sarcomeric formation. 25 CC2 and CC3 cells were identified as proliferative cardiomyocytes expressing genes that regulate cell cycle and cell division, such as TOP2A, CDK1, PCNA, and HIST1H4C ( Figure 3C ). Cluster CC1 was found to be hepatocyte-like cells, expressing TTR (transthyretin) and AFP (α-fetoprotein; Figure 3C and 3H). Cluster CC6 was TAGLN (transgelin)-expressing vascular smooth muscle-like cells ( Figure 3C and 3H) . Thus, the current iPSC-EC differentiation protocol generates a pure population of bona fide iPSC-ECs but also large numbers of cardiomyocytes, as well as other cell types of mesodermal lineage by day 12 of differentiation.
Unique Molecular Signatures Define Heterogeneous Populations of iPSC-ECs
To elucidate the heterogeneity of differentiated iPSC-ECs, the iPSC-EC cluster (cluster 5) at day 12 was isolated as an independent Seurat object, and subclustering was performed ( Figure 4A ). Four iPSC-EC subclusters were generated, with all clusters showing high level of expression of pan-endothelial markers KDR and CDH5 and no expression of cardiac genes TNNT2 or NKX2-5 ( Figure 4B ). Each subcluster is defined by a unique set of differentially expressed genes ( Figure 4C ). For example, CLDN5 is expressed throughout the majority of iPSC-ECs but is particularly enriched in 1 of the 4 subclusters ( Figure 4D) . Similarly, expressions of APLNR, GJA5, and ESM1 were enriched in each of the subclusters, and hence these 4 membrane protein coding genes were used to distinguish each subcluster ( Figure 4D ). Pathway enrichment analysis of the 4 iPSC-EC subclusters revealed their biological function ( Figure 4E ). CLDN5+ cluster represented metabolically active iPSC-ECs with expression of genes related to mitochondrial integrity and metabolic function, such as GIMAP5, HPGD, and CAV1 ( Figure 4D and 4E). APLNR+ cluster represented inflammation-responsive iPSC-ECs with expression of genes related to innate immune response, such as RAGE receptor binding ( Figure 4D and 4E). GJA5+ iPSC-ECs showed robust expression of 4 genes related to arterial EC development in ANXA1, LTBP1, GJA5, and HAND2, indicating that GJA5 can be used as a robust marker for human arterial iPSC-ECs [26] [27] [28] ( Figure 4D  through 4F ). ESM1+ iPSC-ECs showed gene ontologies for angiogenesis, regulation of cell death, and cellular response to chemical stimulus and stress, representing activated iPSC-ECs ( Figure 4F) . ESM1 is thus a robust marker for human iPSCECs in the activated state, which can be used to distinguish iPSC-ECs under inflammatory or angiogenic conditions from the senescent state. The expression of enriched genes in the 4 subpopulations was confirmed in bulk RNA-seq data of human pluripotent stem cell-derived ECs and endothelial progenitor cells from independent studies 29, 30 (Online Figure VI) .
Arterial and Venous Classification of iPSC-ECs
Expressions of traditionally known markers for arterial, venous, and lymphatic endothelial specification 19 were investigated. Arterial endothelial genes of NRP1, EFNB2, and NOTCH1 were highly expressed in the majority of iPSC-EC clusters, whereas venous endothelial genes of EPHB4, NR2F2, and NOTCH4 were modestly expressed in iPSC-EC clusters (Online Figure VIIA) . In particular, expression of venous genes was nearly absent in the GJA5+ cluster, which supports our identification of the cluster as arterial-specific iPSC-ECs ( Figure 4F ). Few iPSC-ECs expressed PROX1 and PDPN-markers of lymphatic ECs (Online Figure VIIA) . The number of iPSC-ECs of each subtype was counted and plotted as Venn diagram (Online Figure VIIB) . Arterial iPSC-ECs were the greatest in number, and their population increased by 4-fold from day 8 to 12. Expression of iPSC-EC genes was also confirmed in human aortic ECs and HUVECs (human umbilical vein endothelial cells; Online Figure VIB ).
Discussion
Here, we use a monolayer-based, chemically defined differentiation protocol to generate bona fide iPSC-ECs. Resulting iPSC-ECs exhibit cobblestone-like morphology and endothelial function, indicating the patient-specific ECs can be used for vascular disease modeling and drug screening. 6 However, the iPSC-EC differentiation protocol suffers from several limitations, most notably in the low yield and significant heterogeneity of the derived bona fide iPSC-ECs. To address these problems, we performed droplet-based scRNA-seq of human iPSCs subjected to EC differentiation and analyzed thousands of cells per sample in parallel.
Our scRNA-seq data reveal the current differentiation protocol generates cells of several mesodermal lineages. A large number of differentiated cells were cardiomyocyte-like cells, expressing TNNT2 and NKX2-5. These cells were divided into 3 transcriptionally distinct groups: a proliferative cardiomyocyte cluster, a functionally immature cardiomyocyte cluster, and atrial-like cardiomyocyte cluster. After mesodermal formation by GSK-3 inhibition, the continuous exogenous addition of VEGF in the protocol is intended for differentiation of vascular progenitor cells and ECs. However, VEGF has also been shown to promote cardiomyocyte differentiation from pluripotent stem cells. [31] [32] [33] Previous studies have shown VEGF activates ERK (extracellular signal-regulated kinases) and JNK (c-Jun N-terminal kinases) signaling pathways in cardiac progenitor cells and cardiomyocytes that express high levels of the VEGF receptors FLT1 and KDR. 31, 34 During embryonic stem cell differentiation, VEGF was shown to increase the levels of cardiac-specific proteins TNNI1 and NKX2-5, which were highly expressed in the cardiomyocyte-like cells derived from the human iPSC-EC differentiation. 31 A low percentage of cells from the differentiation protocol were hepatic-like cells. The hepatic-like cells increased by 10-fold from day 8 to 12 of differentiation, indicating a rapid expansion during the late phase of iPSC-EC differentiation. VEGF has been previously shown to promote hepatic maturation during the final stage of hepatocyte-like cells from iPSCs. 35 Another low percentage of non-ECs was vascular smooth muscle cells, whose number modestly decreased from day 8 to 12 of differentiation.
Transcriptomic analysis of bona fide iPSC-ECs on the final day of differentiation identified 4 distinct populations of iPSC-ECs, noted by enriched expressions of CLDN5, APLNR, GJA5, and ESM1, respectively. Regulation of various signaling pathways controls biological and physiological functionality of ECs. 36, 37 Likewise, the identified iPSC-EC subpopulations displayed enriched expression of genes that together indicate specialized biological functions as metabolically active (CLDN5+), immune-responsive (APLNR+), arterial (GJA5+), and activated (ESM1+) ECs.
In conclusion, we performed large-scale scRNA-seq to better understand the limitations of currently existing iPSC-EC differentiation protocol and to resolve the transcriptional heterogeneity of the resulting iPSC-ECs. Copresence of various endothelial subtypes in iPSC-ECs currently confines the use of the cells to uncover mechanisms of specific vascular disease conditions, such as arterial hypertension, aortic diseases, vasculopathies, and lymphedemas. Based on the findings from this study, future efforts will aim to enable derivation of iPSC-ECs of specific origin and function, which will be necessary for effective disease modeling and for elucidation of molecular mechanisms of vascular diseases. Improved versions of patient-specific iPSC-ECs can also be used as a source of autologous cells for cardiovascular regenerative medicine, where iPSC-ECs of fitting origin and function can replace the damaged ECs in ischemic conditions.
